Long noncoding RNA CASC2 inhibits ox-LDL-mediated vascular smooth muscle cells proliferation and migration via the regulation of miR-532-3p/PAPD5

Chenjing Wang1*, Jin Zhao1, Xiaodong Nan2, Zhong Guo1, Shuangsheng Huang1, Xiaokun Wang1, Feng Sun1 and Shijie Ma1

Abstract

Background: Studies have demonstrated that long noncoding RNAs (lncRNAs) have essential impacts on the development of atherosclerosis (AS). This study aimed to identify the role and functional mechanism of IncRNA CASC2 in the development and migration of vascular smooth muscle cells (VSMCs).

Method: The serum of 40 pairs of AS patients and healthy volunteers were collected and the expression of CASC2 was evaluated. qRT-PCR and western blotting were carried out to examine the expression levels of mRNA and protein level, respectively. Cell proliferation assay, colony formation assay, transwell migration assay, dual-luciferase reporter assay, and wound healing assay were conducted to evaluate cell proliferation, colony formation, migration, transcription, targeting, and self-restoration.

Results: The expression levels of CASC2 were decreased, while the expression levels of miR-532-3p were elevated in AS patient samples and VSMCs. Overexpression of CASC2 inhibited the proliferation and migration of VSMCs and enhanced cell apoptosis. CASC2 inhibited the expression of miR-532-3p, and inversely upregulated the expression of PAPD5, which was a target of miR-532-3p. In addition, knockdown of miR-532-3p-mimic and PAPD5 could attenuate the impact of overexpression of CASC2 on proliferation, migration, and apoptosis in ox-LDL-VSMCs.

Conclusion: CASC2 suppressed cell reproduction and promoted cell apoptosis by regulating the miR-532-3p/PAPD5 axis in ox-LDL-mediated VSMCs. This might be important for AS therapeutics.

Keywords: CASC2, Atherosclerosis, miR-532-3p, PAPD5

Background

Atherosclerosis (AS), a high-risk factor for cardiovascular diseases (Libby et al., 2002), is one of the top causes of heart disease-related morbidity and mortality all over the world (Hansson, 2005). The development of atherosclerosis is related with multiple processes, including the production of pro-inflammatory factors (Ross, 1999), dysfunction of vascular smooth muscle cells (VSMCs) (Bennett et al., 2016), and dysregulation of specific RNAs and proteins (Burd et al., 2010). The abnormal proliferation, migration, apoptosis, and irregular expression of involved proteins in VSMCs contribute to the formation of atherosclerosis (Dzau et al., 2002; Robbins et al., 2013). Even with advancement and development in the understanding of atherosclerosis, the prediction and treatment still face enormous challenges, which make atherosclerosis-induced cardiovascular diseases significant health concerns for many people.
Long non-coding RNAs (lncRNAs, > 200 nt) are demonstrated to participate in a wide variety of biological and pathological processes (Wapinski & Chang, 2011), such as carcinogenesis (Shao et al., 2016) and chronic diseases (Chen et al., 2012). LncRNAs are reported to modulate gene expression epigenetically at transcriptional and post-transcriptional levels, and are involved in multiple signaling pathways (Yang et al., 2014). Growing evidence has suggested that IncRNAs play critical roles in regulating the initial and development of atherosclerosis (Aryal et al., 2014; Chen et al., 2017). For instance, one study demonstrated that IncRNA GAS5 regulated the apoptosis of macrophages and vascular endothelial cells in atherosclerosis (Chen et al., 2017). LncRNA CASC2 is widely reported in the regulation of different human cancers (Liao et al., 2017; Cao et al., 2016). Up-regulated expression of lncRNA CASC2 was reported to inhibit the development of malignant melanoma through regulating miR-18a-5p/RUNX1 (Zhang et al., 2019). In this study, we aimed to explore the roles of CASC2 in the proliferation of vascular smooth muscle cells and the underlying mechanisms in atherosclerosis.

MicroRNAs (miRNAs, 20–22 nt) are identified as crucial regulators of human diseases by binding to a untranslated region (3′-UTR) of target messenger RNAs (mRNAs) to negatively modulate gene expression (Croce & Calin, 2005; Khvorova et al., 2003). MiR-532-3p is a highly conserved miRNA that plays essential roles in cell development, differentiation, and proliferation (Wang et al., 2015; Han et al., 2019). For example, one study reported that miR-532-3p regulated KIFC1 and promoted epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via the gankyrin/AKT signaling pathway (Tan et al., 2019). In addition to its roles in tumors, miR-532-3p was also found to be involved in cardiac physiology. It was reported that miR-532-3p regulated mitochondrial fusions via targeting apoptosis repressor with caspase domain (Aryal et al., 2014). For instance, it was reported to interact with several miRNAs, such as miR-21 in pCR2-positive metastatic gastric cancer (Boele et al., 2014) and miR-4728 cancer and other proliferative diseases (Newie et al., 2016).

Oxidized low-density lipoprotein (ox-LDL) has been widely reported in the pathological phenotype transformation of VSMCs in AS (Gao & Liu, 2017). Recent studies showed that low concentrations of ox-LDL (0–100 μg/ml) promote the lipid uptake by macrophage and increase the proliferation and migration of VSMCs. Considering the importance of ox-LDL in inducing atheroma (Ding et al., 2012; Tian et al., 2015), we aimed to investigate the roles of IncRNA CASC2, miR-532-3p and PAPD5 in the ox-LDL induced phenotypic and functional changes of VSMCs, and further demonstrate the molecular mechanisms in the development of atherosclerosis.

Methods

Clinical samples

Forty AS patients and forty healthy volunteers (age range 50 to 70 years old and 30% females) were recruited in this study. All of the participants signed the informed consent. This study was approved by the Ethical Committee in Medical College of Northwest Minzu University Health Science Center. Blood sample (10 ml) from each participant was collected and maintained at 25 °C for 1h. Serum samples were collected and total RNAs were extracted by Trizol reagent (Invitrogen, US).

Cell culture

Human aortic-VSMCs (HA-VSMCs) were provided by American Type Culture Collection (US) and kept in F-12K medium with 10% FBS (Invitrogen, US), 0.05 mg/ml ascorbic acid (Sigma, US), 10 μg/ml insulin (Sigma, US), 10 μg/ml transferrin (Sigma, US), 30 μg/ml endothelial cell growth supplement (Cell application, US), 0.01 μg/ml sodium selenite (Sigma, US), 10 mM HEPES (Sigma, US), and 10 mM TES (Sigma, US), the culture conditions were 95% humidity and 5% CO2 at 37°C.

Cell transfection and treatment

LncRNA CASC2 was amplified and then cloned into pcDNA3.1 vector (Invitrogen, US) to construct pcDNA-CASC2 overexpression plasmids. CASC2 siRNA (Si-CASC2), siRNA negative control (si-NC), PAPD5 siRNA (si-PAPD5) and PAPD5 si-NC, miR-532-3p mimic and miRNA mimic negative control (miR-NC) were purchased from GenePharma (Shanghai, China). The transfection was carried out by lipofectamine 2000 (Invitrogen, US). For observation of the effect of ox-LDL (Biosynthesis, China) on the expression of CASC2 and miR-532-3p, VSMCs were cultured with 50 μg/ml ox-LDL for two day.

qRT-PCR

Total RNA samples (1 μg) were reverse-transcribed into cDNAs using PrimeScript™ RT reagent Kit with gDNA Eraser (Cat# RR047A, Takara). SYBR Master (TOYOBO, Japan) was used to measure the expression of CASC2, GAPDH, miR-532-3p and U6. MiR-532-3p and U6 primers were provided by Ribobio (Guangzhou, China). The primer sequences used were:

CASC2 (divergent primer): 5′- GGTGGGGCCTGTCAATCTCTA - 3′ (forward);
CASC2 (divergent primer): 5′- GGTAAGCCCCGCACG GTA-3′ (reverse);

CASC2 (divergent primer): 5′- GGTGGGGCCTGTCAATCTCTA - 3′ (forward);
CASC2 (divergent primer): 5′- GGTAAGCCCCGCACG GTA-3′ (reverse);
ITCH (convergent primer): forward: 5′-GGTGTGGAAGTGGCGTGGT-3′ (forward); reverse 5′-TGGAGGTCAACTTCGTT-3′ (reverse).

miR-532-3p: 5′-CGTTTTCACTGTATG-3′ (forward); reverse: 5′-CAACCGGCGATGGCC-3′ (reverse).

PAPD5: 5′-AAAGCTATGCTATGGCTCGA-3′ (forward); reverse: 5′-GGCACTAAGTGCCAATCAC-3′ (reverse).

GAPDH: reverse: 5′-TGTTGCTCATAGTGACGGGAAC-3′ (reverse).

U6: 5′-ATGATGGCAGTGATAGGGCCC-3′ (forward); reverse: 5′-GATTGGCAGCGATTATACACC-3′ (reverse).

Cell proliferation and colony formation
The transfected cells were seeded into 96-well plates (2000 cells/well) for CCK-8 assay. At 0, 1, 2, 3 and 4 d after seeding, each well was supplied with 10 μl CCK-8 solution (Dojindo, Japan) and cultured for another 1 h at 37 °C in dark. A microplate reader (Tecan, Switzerland) was used to detect the signal at 450 nm. For BrdU incorporation, cells were seeded in 96-well plates (2000 cells/well). After 2 d of transfection, cell proliferation was detected by BrdU cell proliferation assay kit (Cat#5213S, Cell Signaling). For colony formation, cells were seeded in 6-well plates (4000 cells/well). After 14 d, cells were fixed and stained using 0.1% crystal violet. The colonies were recorded.

Cell apoptosis
Cells (1 x 10^5) were harvested and washed with cold PBS, then stained in 5 μL FITC Annexin V (BD, US) and 5 μL Propidium Iodide (PI) for 10 min at 25 °C in dark. Then, 400 μl 1× binding buffer (Cat# CA1020, Solarbio, Beijing, China) was added to each tube. The apoptotic cells were measured by fluorescence-activated cell sorting flow cytometer (BD, US).

Transwell assay
The 24-well transwell chambers with Matrigel (BD, USA) were used to determine VSMCs cell migrations. Briefly, after transfection with CASC2, miR-532-3p, PAPD5 and the relative siRNA, the VSMCs were resuspended in 200 μl serum-free medium, and 40,000 cells were loaded into the upper chambers, and the lower chambers were filled with 500 μl medium with or without 10 μg/ml ox-LDL. After 1 d of incubation, the migrated cells were fixed with 4% paraformaldehyde for 15–20 min, then stained with DAPI (1:2000, Sigma-Aldrich, USA) for 10 min at room temperature, and finally analyzed by a microscope (Olympus) in three random fields for each well.

Dual-luciferase assay
CAS2-WT (wild-type) or CAS2-MUT (mutant) and PAPD5 were cloned into pmirGLO miRNA Target Expression vectors. VSMCs were co-transfected with these plasmids and miR-532-3p inhibitor or mimic. Luciferase activities were detected after 2 d using a dual-luciferase system (Promega, USA). The expression of a luciferase reporter was quantitated by the ratio of Firefly and Renilla luciferase signals. Each experiment was repeated for three times.

Wound healing assay
Wound-healing assay was also used to assess the cell migration of VSMCs. Cells were inoculated to generate a confluent monolayer in 6-well plate. By a 200 uL sterile pipette tip, a scratch was made to the confluent cells, causing a wound. After 2 d of culture, a microscope was used to assess the scratch-induced wound. The results were recorded by Image J through the proportion of wound closure, with the primitive width of the scratch at 100%. The image was represented one from at least 3 repetitive experiments.

Western blot
Proteins were isolated by RIPA lysis buffer (Beyotime) and measured by BCA kit (Thermo Fisher Scientific, US). Protein samples (50 μg) were separated by SDS-PAGE and transferred to PVDF membrane (Millipore, US). After blocking by 5% skim milk for 1 h, the membrane was incubated with anti-PCNA (1:500; Santa Cruz Biotechnology, USA), MMP-2 (1:500; SCB), MMP-9 (1:500; SCB), PAPD5 (1:1000; CST) and GAPDH (1:1000; CST). After being washed with PBS, the membrane was treated with horseradish peroxidase linked secondary antibody. Clarity Max™ Western ECL Substrate was used to quantify the signal (BR). SCB stands for Santa Cruz Biotechnology (US); CST stands for Cell Signaling Technology (US) and BR stands for Bio-Rad (US).

Statistical analysis
All results were expressed as mean ± SD of more than three independent experiments. Differences between two groups and among multiple groups were explored by t-test and one-way ANOVA, respectively. P < 0.05 represented statistically significant differences.

Results
LncRNA CASC2 was down-regulated in AS samples and HA-VSMCs
The expression of LncRNA CASC2 was detected by qRT-PCR assay. It showed that the expression levels of
CASC2 were significantly inhibited in AS patient serum compared to that in healthy samples (Fig. 1a). In addition, in vitro experiment also demonstrated that ox-LDL stimulation results in the decreased expression levels of CASC2 in HA-VSMCs in a dose-dependent (Fig. 1b) and time-dependent (Fig. 1c) manner. The data suggested that CASC2 might be an essential mediator in AS progression.

**CASC2 sponged miR-532-3p in AS patients**

Through bioinformatics analysis, we found that CASC2 shared binding sequences with miR-532-3p (Fig. 2a), which is predicted by Starbase, and RegRNA or PITA database. As shown in Fig. 2b, overexpression of miR-532-3p greatly reduced the luciferase activities of CASC2-WT but has no effect on CASC2-MUT. Figure 2c demonstrated that CASC2 greatly elevated the luciferase activities of CAS2 but significantly inhibited the luciferase activities of miR-532-3p. In addition, knockdown of CASC2 elevated the expression of miR-532-3p, but overexpression of CASC2 inhibited the expression of miR-532-3p in VSMCs (Fig. 2c). Furthermore, the expression levels of miR-532-3p were dramatically elevated in the serum of AS patients than that in healthy ones (Fig. 2d). As shown in Fig. 3e, a negative relationship was observed between the expression of CASC2 and miR-532-3p in the serum of AS patients (r = 0.533, P < 0.001). These data indicated that CASC2 exerted its functions through the sponge with miR-532-3p.

**CASC2 sponged and sequestered miR-532-3p to upregulate the expression of PAPD5**

To further evaluate the functional genes downstream of miR-532-3p. Targetscan was used and it predicted that PAPD5 might be a target gene of miR-532-3p (Fig. 3a). In addition, overexpression of miR-532-3p inhibited the luciferase activity of PAPD5-WT, but had no effect on PAPD5-MUT through the dual-luciferase reporter assay (Fig. 3b). As shown in Fig. 3c and d, the expression of PAPD5 was inhibited in miR-532-3p transfected VSMCs, but upregulated by CASC2 at both mRNA and protein levels. Figure 3e showed that the expression levels of

![Fig. 1](image_url) LncRNA CASC2 was downregulated in AS patient serum and ox-LDL-stimulated VSMCs. a The expression of CASC2 in serum of AS patients and healthy people through qRT-PCR. b The expression of CASC2 after treatment with 0, 25, 50, 75 μg/ml ox-LDL for 1 d. c The expression of CASC2 after treatment with 50 μg/ml ox-LDL for 0, 1, 2, and 3 d through qRT-PCR. **P < 0.01; ***P < 0.001
**Fig. 2** CASC2 sponged miR-532-3p in AS patients. 
**a** The common binding sequences between CASC2 and miR-532-3p by Starbase and RegRNA or PITA database. 
**b** The luciferase activities in VSMCs co-transfected with miR-532-3p mimic and CASC2-WT or CASC2-MUT vector. 
**c** qRT-PCR for miR-532-3p expression in VSMCs with si-CASC2 or CASC2. 
**d** Western blotting for the expression of PAPD5 protein in VSMCs co-transfected with miR-532-3p mimic or miR-NC, and CASC2 or control. 
**e** Pearson’s correlation between CASC2 and miR-532-3p in the serum of AS patients ($r = -0.533$, $P < 0.001$). **$P < 0.01$; ***$P < 0.001$ vs. control group, # vs. miR-532-3p mimics group.

**Fig. 3** CASC2 sponged and sequestered miR-532-3p to up-regulate the expression of PAPD5. 
**a** The common binding sequences of miR-532-3p and PAPD5 by Targetscan analysis. 
**b** The luciferase activities of VSMCs co-transfected with miR-532-3p mimic and PAPD5-WT or PAPD5-MUT. 
**c** qRT-PCR for the expression of PAPD5 in VSMCs co-transfected with miR-532-3p mimic or miR-NC, and CASC2 or control. 
**d** Western blotting for the expression of PAPD5 protein in VSMCs co-transfected with miR-532-3p mimic or miR-NC, and CASC2 or control. 
**e** Pearson’s analysis of CASC2 and PAPD5 in serum of AS patients ($r = 0.460$, $P < 0.001$). * vs. control group, # vs. miR-532-3p mimics group. **$P < 0.01$, ##$P < 0.01$
PAPD5 were significantly decreased in the serum of AS patients in contrast to that in healthy people. As shown in Fig. 3f, the expression of CASC2 was positively related to the expression of PAPD5 in AS serum (r = 0.460, P < 0.001). These results demonstrated that CASC2 elevated the expression of PAPD5 by sponging miR-532-3p in AS.

CASC2 suppressed the proliferation of VSMCs through modulating miR-532-3p/PAPD5

To further explore the role of CASC2 on the proliferation, apoptosis and migration of VSMCs. CASC2 significantly inhibited the viabilities, proliferation, and colony formation of VSMCs, but these effects were abrogated by miR-532-3p overexpression (Fig. 4a-c). Similarly, CASC2 overexpression increased the cell apoptosis and it could be reversed by upregulation of miR-532-3p (Fig. 4d). However, co-transfection of CASC2 with si-PAPD5 has the same effect with co-transfection of CASC2 with miR-532-3p mimic on VSMCs, which partly attenuated the effect of CASC2.

CASC2 suppressed the migration of VSMCs through modulating miR-532-3p/PAPD5

We next performed transwell assay and wound healing assay to detect whether CASC2 had effect on VSMCs cell invasion and migration. The results illustrated that overexpression of miR-532-3p greatly reverses the CASC2-induced cell migration (Fig. 5a). Meanwhile, the wound healing assay also showed similar results (Fig. 5b). Moreover, to explore the signaling pathways involved in cell proliferation and migration, the expression of proliferation- and migration-related proteins, including PCNA, α-SMA, MMP-2, and MMP-9, were detected. As shown in Fig. 5c, overexpression of CASC2 suppressed the expression of PCNA, α-SMA, MMP-2, and MMP-9. Besides, CASC2 co-transfection with si-PAPD5 exhibited the same effects as co-transfection with miR-532-3p mimics on VSMCs. As a result, overexpression of miR-532-3p or
silencing of PAPD5 could reverse CASC2-induced inhibition of growth and migration in VSMCs.

Discussions

Studies have proved that dysregulation of certain lncRNAs is closely related to human disease. For atherosclerosis, lncRNAs have also been discovered to exert promotive roles in the proliferation of VSMCs. For example, IncRNA H19 was reported to promote atherosclerosis by regulating the MAPK and NF-kB signaling (Pan, 2017). In their study, H19 was considerably upregulated in AS patients and VSMCs (Pan, 2017). From the qRT-PCR results in our experiments, we found that CASC2 was significantly downregulated in human AS samples compared to that in healthy samples and normal cells. As a new indicator for AS, CASC2 could be an important mediator in AS progression.

Previous studies indicate that lncRNAs can sponge their corresponding miRNAs, and exert their biological functions to regulate specific cells (Cao et al., 2016). For example, CASC2 was found to sponge miR-181a to modulate glioma growth and resistance to temozolomide (TMZ) through the PTEN pathway (Liao et al., 2017). Another study reported that down-regulation of CASC2 by miRNA-21 could increase the proliferation and migration of renal carcinoma cells. In our experiments, Starbase and dual-luciferase assay confirmed that CASC2 could target to miR-532-3p. Moreover, the
expression of miR-532-3p was significantly upregulated in the serum of AS patients than that in healthy controls. It demonstrated that CASC2 exerted its functions through the sponging of miR-532-3p.

Non-canonical poly(A) polymerase PAPD5 can adenylate the post-transcription of miR-21, and affect the proliferation of corresponding cells in cancer (Boele et al., 2014). Targetscan predicts that PAPD5 might be a target of miR-532-3p. In the luciferase reporter assay, we noticed that overexpression of miR-532-3p inhibited the luciferase activities of PAPD5-WT. The expression of PAPD5 was relieved in miR-532-3p transfected VSMCs but were attenuated by CASC2 at both mRNA and protein levels. Moreover, the expression levels of PAPD5 were significantly decreased in the serum of AS patients in contrast to that in healthy people. PAPD5-mediated adenylation of miRNA-21 is disrupted in cancer (Koppers-Lalic et al., 2016). Here, we found that CASC2 elevated the expression levels of PAPD5 by sponging miR-532-3p in AS, which might inhibit the cell proliferation of VSMCs.

LncRNA UCA1 was shown to sponge miR-26a to regulate the migration and proliferation of vascular smooth muscle cells (Tian et al., 2018). Similarly, the expression of miR-26a was up-regulated in ox-LDL (50 mg/l) induced VSMCs, and UCA1 antagonized the effect of miR-26a on the downregulation of its target PETN and contraction phenotype (Tian et al., 2018). In our experiments, CASC2 significantly inhibited the viabilities, cell proliferation, and colony formation of VSMCs, but this effect was abrogated by overexpression of miR-532-3p. Overexpression of miR-532-3p greatly reversed the CASC2-induced cell apoptosis, migration, and cell restoration from wound. In addition, overexpression of CASC2 suppressed the expression of proliferation-related proteins and migration-related proteins, including CNA, α-SMA, MMP-2, and MMP-9. CASC2 co-transfection with si-PAPD5 had the effects as co-transfection with miR-532-3p mimics on VSMCs. In consistence with previous report, overexpression of miR-532-3p or silencing of PAPD5 could reverse CASC2-induced growth and migration inhibition of VSMCs. CASC2 could suppress cell proliferation and cell migration in VSMCs through modulating miR-532-3p/PAPD5. The schematic model of our research hypothesis was represented in Fig. 6.

Conclusions
CASC2 suppressed cell reproduction and promoted cell apoptosis via regulating the miR-532-3p/PAPD5 axis in AS serum. This might be essential for AS therapeutics.

Abbreviation
VSMCs: Vascular smooth muscle cells; lncRNAs: Long noncoding RNAs; AS: Atherosclerosis; ox-LDL: Oxidized low-density lipoprotein

Acknowledgements
Not applicable.

Authors’ contributions
Chenjing Wang supervised the whole study, data analysis, manuscript preparation. Jin Zhao; Xiaodong Nan; Zhong Guo; Shuangsheng Huang; Xiaokun Wang; Feng Sun; Shijie Ma collected and analyzed the data, manuscript preparation. The authors read and approved the final manuscript.

Funding
This work was supported by Research Fund for institutions of higher learning of Gansu Province (No. 2017B-81); The Fundamental Research Fund for the Central Universities from Northwest Minzu University, China (No. 31920180023); Fund of the National Natural Science Foundation of China (No. 81360490).

Availability of data and materials
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The present study was approved by the Ethics Committee of Medical College of Northwest Minzu University Health Science Center. The research has been carried out in accordance with the World Medical Association Declaration of Helsinki. All patients and healthy volunteers provided written informed consent prior to their inclusion within the study.

Consent for publication
Not applicable.

Competing interests
None declared.

Author details
1 School of Basic Medical Sciences, Northwest Minzu University Health Science Center, No. 1, XibeiXincun Chengguan District, Lanzhou City, Gansu Province 730030, People’s Republic of China.
2 Department of intensive care unit, Gansu Provincial Corps Hospital of Chinese People’s Armed Police Force, Lanzhou City, Gansu Province 730050, People’s Republic of China.

Received: 10 December 2019 Accepted: 13 July 2020

Published online: 22 July 2020

References

Ayala B, Rottman N, Fernández-Hernando C. Noncoding RNAs and atherosclerosis. Curr Atheroscler Rep. 2014;16(5):407.

Bennett MR, Sinha S, Ovens GC. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702.

Boele J, et al. PAPD5-mediated 3′ end processing of noncanonical polyadenylation mediates 3′ alternative polyadenylation. Proc Natl Acad Sci. 2018;115(20):E4502–10.

Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and circular RNA variants (isomiRs) in urine extracellular vesicles. Oncotarget. 2016;7(25):37812.

Tian L, et al. Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells. Mol Med Rep. 2015 Oct;12(4):4995–5002.

Tian S, Yuan Y, Li Z, Gao M, Lu Y, Gao J. LncRNA-CASC2 sponges miR-26a to regulate the migration and proliferation of vascular smooth muscle cells. Gene. 2018;673:159–66.

Wang J, et al. MicroRNA-532-3p regulates mitochondrial fission through targeting aap1 and correlates with atherosclerosis risk. PLoS Genet. 2010;6(10):e1001233.

Cao Y, Xu R, Xu X, Zhou Y, Cui L, He X. Downregulation of IncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep. 2016;14(1):1019–25.

Chen G, et al. LncRNA-Disease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2012;41(D1):D123–28.

Chen L, et al. Exosomal IncRNA GAS5 regulates the apoptosis of macrophages and vascular endothelial cells in atherosclerosis. PLoS One. 2017;12(9):e0185406.

Croce CM, Calin GA. miRNAs associated with cancer. Cell. 2005;120(1):65–70.

Ding Z, et al. Effect of oxidized low-density lipoprotein concentration polarization on human smooth muscle cells’ proliferation, cycle, apoptosis and oxidized low-density lipoprotein receptor-1 expression. J R Soc Interface. 2012 Jun 7;9(71):1233–40.

Dzialovich I, Braun-Dullaeus RC, Seoane J, Dikic I. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8(11):1249.

Gao S, Liu J. Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease. Chronic Dis Transl Med. 2017;3(2):126–33.

Han J, et al. KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. Oncogene. 2019;38(3):406.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

Khorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003;115(2):209–16.

Koppers-Lalic D, et al. Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget. 2016;7(16):22566.

Liao Y, et al. LncRNA CASC2 interacts with miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway. J Cell Biochem. 2017;118(7):1899–909.

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.

Newie L, et al. HER2-encoded mir-4728 forms a receptor-independent circuit with miR-21-5p through the non-canonical poly (A) polymerase PAPD5. Sci Rep. 2016;6:35664.

Pan J. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(2):322–8.

Rammelt C, Bilen B, Zavolan M, Keller W. PAPD5, a noncanonical poly (A) polymerase with an unusual RNA-binding motif. RNA. 2011;17(9):1737–46.

Robbins CS, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19(9):1166.

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26.

Shao Y, et al. LncRNA-RMRP promotes carcinogenesis by acting as a novel biomarker for gastric cancer. Oncol Lett. 2016;12(5):37812.

Tian J, et al. Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells. Mol Med Rep. 2015 Oct;12(4):4995–5002.

Tian S, Yuan Y, Li Z, Gao M, Lu Y, Gao J. LncRNA-CASC2 sponges miR-26a to regulate the migration and proliferation of vascular smooth muscle cells. Gene. 2018;673:159–66.

Wang J, et al. MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity. Cell Death Dis. 2015;6:e1677.

Wapinski O, Chang J. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21(6):335–44.

Yang G, Lu X, Yuan L. LncRNA D2A linker between RNA and cancer. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechan. 2014;1859(11):1097–109.

Zhang Y, et al. Exosomal IncRNA CASC2 may inhibit malignant melanoma development through regulating miR-18a-5p/RUNX1. Oncol Res Featuring Preclin Clin Cancer Therapeutics. 2019;27(3):371–7.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions